Articles published by uniQure Inc.
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
November 05, 2024
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
October 15, 2024
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
September 23, 2024
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 07, 2024
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 19, 2023
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
November 29, 2023
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 07, 2023
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 24, 2023
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 01, 2023
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From uniQure Inc.
Via GlobeNewswire
Tickers
QURE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free